Bill

XBP Europe Holdings, Inc. Reports Full Year 2023 Results

Retrieved on: 
Monday, April 1, 2024
Capital expenditure, Growth, TCV, Bill, Operating cost, Sale, XBP, Adjustment, Bookkeeping

LONDON and SANTA MONICA, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- XBP Europe Holdings, Inc. (“XBP” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills and payments and related solutions and services seeking to enable the digital transformation of its clients, announced today its financial results for the full year ended December 31, 2023.

Key Points: 
  • “We start the year as a newly listed public company, having completed our long-awaited business combination towards the very end of 2023.
  • We will keep our employees and the investor community apprised of our progress in the coming weeks and months,” said Andrej Jonovic, Chief Executive Officer of XBP.
  • Net Loss: Net loss for 2023 was $11.0 million, compared with a net loss of $7.9 million in 2022.
  • Adjusted EBITDA(1): Adjusted EBITDA for 2023 was $11.6 million, a decrease of 20.0% compared to $14.5 million in 2022.

Silicon Valley Community Foundation granted more than $3 billion to Bay Area nonprofits in 2023

Retrieved on: 
Friday, March 29, 2024
Community, Health, Culture, Organization, Bill, Environment, Social justice, Education, Food, Second Harvest Toronto, Silicon Valley Community Foundation, Silicon, SVCF, Casino

●     $3.1 billion supported organizations in the 10 Bay Area Counties, $186 million of which supported nonprofits in SVCF’s two core counties -- San Mateo County and Santa Clara County

Key Points: 
  • Mountain View, CA, March 29, 2024 (GLOBE NEWSWIRE) -- According to preliminary calculations, Silicon Valley Community Foundation (SVCF) distributed $3.1 billion in grants directly to nonprofits in the Bay Area in 2023, more than any other entity in the state of California.
  • In total, SVCF granted $4.58 billion to more than 5,500 nonprofits and community organizations worldwide.
  • “I’m always impressed at our donors’ generosity but what they gave in 2023 went beyond anything I had imagined,” said Nicole Taylor, President and CEO of Silicon Valley Community Foundation.
  • In Santa Clara County, Second Harvest of Silicon Valley was one of the top recipients of SVCF grants in 2023.

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Genetics, Clinical Trials, Master of Science, Bill, Erasmus University Rotterdam, Pfizer, Rotterdam School, Novartis, Business administration, Acquisition, Cancer, Protein engineering, Biology, Investment, DSM (company), Malaria, Pharmaceutical industry

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.
  • Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support.
  • “Bart’s exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor as we advance our maturing clinical-stage pipeline of drug candidates and continue to explore our XmAb® platforms against novel biology,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
  • He began his career within the life sciences and global health sectors at Novartis, in roles of increasing responsibility within global financial planning and analysis.

Bottomline Expands Expert Legal Bill Review Service

Retrieved on: 
Tuesday, March 19, 2024
Spend, CLM, ROI, Organization, Property, Third party, Bill, Suite, Product management, P&C

PORTSMOUTH, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- Bottomline, a global leader in business payments, today announced the expansion of its Expert Legal Bill Review Service for Property and Casualty (P&C) Insurance Carriers and Corporate Legal organizations.

Key Points: 
  • PORTSMOUTH, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- Bottomline, a global leader in business payments, today announced the expansion of its Expert Legal Bill Review Service for Property and Casualty (P&C) Insurance Carriers and Corporate Legal organizations.
  • Initially exclusive to customers utilizing Bottomline’s Legal-X or Legal eXchange platforms, the Expert Legal Bill Review service has now been extended to organizations using any legal spend or legal eBilling system, including Corporate Legal.
  • This means that legal teams can seamlessly leverage the industry’s premier expert legal bill review service without the need for platform changes.
  • The 2023 Claims Litigation Management Alliance (CLM) Study, performed by Suite 200, provides third-party confirmation of Bottomline’s leadership and ROI in 3rd party bill review services, where our analysis of the data shows Bottomline Expert Legal Bill Review customers achieve significantly better results.

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Mother, Research, Breast milk, Conference call, Development, Bill, Webcast, COVID-19, SAN, VOC, GI, Messenger, XBB, NHP, SARS-CoV-2, Insurance, Investment, Clinical trial, Antibody, Safety, Vaxart, Nextgen, Vaccine, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
  • Financial Results for the Full Year Ended December 31, 2023
    Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
  • Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2023 today, beginning at 4:30 p.m.

Women in the Digital Economy Fund: USAID, the Bill & Melinda Gates Foundation, and Partners Launch WiDEF

Retrieved on: 
Tuesday, March 12, 2024
CARE, Microsoft, Development, Digital inclusion, Bill, Woman, Health, Education, USAID, Society, Internet, Research, Policy, Literacy, United, Private sector, International development, Digital technology, Digital divide, GSMA, Korea International Cooperation Agency, Toy

We need a future in which women are empowered to participate as equal citizens in our increasingly digital world.

Key Points: 
  • We need a future in which women are empowered to participate as equal citizens in our increasingly digital world.
  • "I'm proud of our support for the Women in the Digital Economy Fund.
  • Overcoming the gender digital divide is crucial to unlock the potential of women in the digital era.
  • "Launching WiDEF is indeed a special moment, one that reflects real commitment and determination to address the stubborn gender digital divide and open the possibilities for women in the digital economy.

TeleVox Introduces New Platform for Physician Offices to Ease Scheduling Burden and Reduce No-Shows

Retrieved on: 
Tuesday, March 12, 2024
Electronic health record, Patient, Bill, Calendar, Physician, Health, Nursing

TeleVox Practice Edition offers a suite of services designed specifically to help physicians and their staff overcome common industry challenges, including inefficient scheduling processes, poor communication, low retention, and reputation management.

Key Points: 
  • TeleVox Practice Edition offers a suite of services designed specifically to help physicians and their staff overcome common industry challenges, including inefficient scheduling processes, poor communication, low retention, and reputation management.
  • “Communication must be at the center of the patient/physician relationship, but too many practices fall behind due to staffing challenges or inefficient technology,” said Vik Krishnan, President at TeleVox.
  • Backed by world class technical support, Practice Edition blends innovation and affordability tailored for today’s digital healthcare environment.
  • “Practice Edition is an active, persistent and conversational channel that ultimately meets the patient where they are.”
    For more information about TeleVox Practice Edition, please visit https://televox.com/healthcare/physician-practices-2/ .

Antibody Solutions Secures Grant for Challenging Diagnostic Initiative

Retrieved on: 
Thursday, April 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Genetics, LDH, Infection, Bill, RDT, Risk, Public, NGS, Antibody Solutions, Doctor of Philosophy, LMIC, Biology, Malaria, Antibody, Melinda French Gates, Vaccine

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.

Key Points: 
  • Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.
  • The end result is that those RDTs are unable to differentiate between different strains of malaria,” explained John Kenney, PhD, co-founder and president of Antibody Solutions.
  • ”
    Antibody Solutions has already begun work to identify these new antibody reagents by harnessing Cellestive, its antibody discovery platform, that includes multiple discovery pathways such as hybridoma library, primary B-cell screening, and guided next-generation sequencing (NGS).
  • The grant from the foundation will also allow Antibody Solutions to work with industry experts in both public health and the development and deployment of healthcare solutions in low- and middle-income (LMIC) settings, ensuring that these reagents will be widely available.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Administration, Nontuberculous mycobacteria, Conference, Bill, AN2, Entrepreneurship, NTM, Boron, Tuberculosis, University, Patient, Melioidosis, Data monitoring committee, G&A, MAC, Insurance, Infection, Wellcome Trust, Investment, Clinical trial, Chagas disease, Therapy, Malaria, Safety, Poster, Research and development, Mycobacteroides abscessus, IDSA, Trust, Pharmaceutical industry

Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.

Key Points: 
  • Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.
  • Net loss: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
  • Net loss for the fourth quarter of 2023 was $16.9 million, compared to $11.8 million for the same period during 2022.
  • Cash Position: The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.

Global Cultured Meat Market Size, Trends, Competitors, and Forecasts Report 2023: By 2040, a Projected 60% of the Meat will be Created from Cells Grown Within Bioreactors and Sold Worldwide - ResearchAndMarkets.com

Retrieved on: 
Monday, March 25, 2024
Retail, Agriculture, Natural Resources, Food, Beverage, Aleph Farms, Bioreactor, NCI, Meat, Competition, Market, Cell, Bill, Upside Foods, Global Health, Research, Sale, Seafood, DFJ, Silicon, Investment, European, Cargill, Restaurant, Imagination, Geography, Language, Tyson Foods, Fast food

The "The Global Market for Cultured Meat - Market Size, Trends, Competitors, and Forecasts (2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Market for Cultured Meat - Market Size, Trends, Competitors, and Forecasts (2023)" report has been added to ResearchAndMarkets.com's offering.
  • By 2040, a projected 60% of the meat will be created from cells grown within bioreactors and sold across grocery stores and restaurants worldwide.
  • Over the next 10 to 20 years, the cultured meat market is projected to act as a major disruptor to the conventional meat market.
  • The main objectives of this cultured meat report are to provide the reader with the following details:
    Global market size for cultured meat, segmented by geography and meat type
    Future market size for the cultured meat, segmented by geography, meat type, and year